ArticleClinical and experimental vaccine research2025
Identification of conserved CD8+ T cell epitopes in Nipah virus towards vaccine development using an immunoinformatics approach.
Article in Clinical and experimental vaccine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Developing a treatment for Nipah virus (NiV) infection is necessary due to its high fatality rate, broad host range, and unavailable licensed effective treatment. Therefore, this study aimed to identify candidate epitopes of NiV proteins as immunotherapeutic agents for vaccine development. Materials and Methods: Immunoinformatics was used to identify conserved fragments and candidate CD8+ epitopes in all 6 structural (F, G, L, M, N, and P) and 2 of 3 nonstructural proteins (V and W). Potential cross-reactivity, toxicity, and allergenicity were assessed. The population coverage of each candidate epitope globally and in high-risk regions were analyzed. Selected epitope-human leukocyte antigen (HLA) pairs were docked to analyze binding energy and spontaneity and favorability of complex formation. Results: Conservation analysis of proteins F, G, L, M, N, P, V, and W resulted in 16, 11, 40, 8, 14, 41, 10, and 10 conserved fragments (≥ nonamer), respectively. One hundred and fifty-three conserved CD8+ epitopes are promiscuous binders and are likely to be good major histocompatibility complex I binders (inhibitory concentration 50 <500 nM), non-toxic, non-allergenic, and non-cross-reactive with human antigens (E-value >1.0e-30). The 3 epitopes with the highest population coverage are Conclusion: Results showed promising CD8+ T cell epitopes among the structural and nonstructural proteins of NiV, that possess safety, immunogenicity, and broad population coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.